Topical diphencyprone immunotherapy for cutaneous metastatic melanoma

Australasian Journal of Dermatology

Volumn 50, Issue 4, 2009, Pages 266-271

  Damian, Diona L ^a,b   Shannon, Kerwin F ^b   Saw, Robyn P ^b   Thompson, John F ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Contact hypersensitivity; Diphenlycyclopropenone

Indexed keywords

DACARBAZINE; DIPHENCYPRONE; IMIQUIMOD;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; DRUG DOSE TITRATION; DRUG SENSITIZATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXCISION; FEMALE; FREE TISSUE GRAFT; HUMAN; LUNG METASTASIS; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYCLOPROPANES; HUMANS; MALE; MELANOMA; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 72449145330     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2009.00556.x     Document Type: Article

References (13)

1. Barnetson RS, Halliday GM. Regression in skin tumours: a common phenomenon. Australas. J. Dermatol. 1997 38 (Suppl. 1 S63 5.
2. High WA, Stewart D, Wilbers CRH, Cockerell CJ, Hoang MP, Fitzpatrick JE. Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: a report of 5 cases and assessment of the literature and diagnostic criteria. J. Am. Acad. Dermatol. 2005 53 : 89 100.
3. Hurwitz PJ. Spontaneous regression of metastatic melanoma. Ann. Plast. Surg. 1991 26 : 403 406.
4. Goodnight JEJ, Morton DL. The role of immunotherapy in the management of patients with malignant melanoma. World J. Surg. 1979 3 : 309 320.
5. Buckley DA, Du Vivier AW. The therapeutic use of topical contact sensitizers in benign dermatoses. Br. J. Dermatol. 2001 145 : 385 405.
6. Harland CC, Saihan EM. Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine. Lancet 1989 8660 : 445.
7. Trefzer U, Sterry W. Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma. Dermatology 2005 211 : 370 371.
8. Damian DL, Thompson JF. Treatment of extensive cutaneous melanoma metastases with topical diphencyprone. J. Am. Acad. Dermatol. 2007 56 : 869 871.
9. Wack C, Kirst A, Becker JC, KLutz WK, Brocker EB, Fischer WH. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response. Cancer Immunol. Immunother. 2002 51 : 431 439.
10. von Nida J, Quirk C. Successful treatment of in-transit melanoma metastases using topical 2-4 dinitrochlorobenzene. Australas. J. Dermatol. 2003 44 : 277 280.
11. Wilkerson MG, Connor TH, Wilkin JK. Dinitrochlorobenzene is inherently mutagenic in the presence of trace mutagenic contaminants. Arch. Dermatol. 1988 124 : 396 398.
12. Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Mel. Res. 2008 18 : 405 411.
13. Steinman A, Funk JO, Schuler G, von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J. Am. Acad. Dermatol. 2000 43 : 555 556.